BaxDUO ARCTIC

a Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

Stage: followup
Medicine: Baxdrostat
Population: Primaire preventie coronairlijden
Phase: III
First Patient In: 15 July 2024
Last Patient In: 21 November 2025
Last Patient Last Visit: 10 December 2027

National Lead

J. van der Net

Study Director

dr. P.M. van der Zee

Cardioloog

Office Contact

M.J. van Doorn

WCN